In a prior study of a smaller cohort of early-stage ER+ breast cancer patient tumors, we revealed that cancer resistance to endocrine and CDK4/6 inhibition therapy involves cancer cells shifting from estrogen-mediated signaling to alternative growth signal-mediated proliferation (Griffiths et al, 2021). Here, ESR1 is linked to breast carcinoma.